G 20: Medical Value Travel could be focused on maintaining, improving or restoring health through medical intervention: Dr V K Paul

There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22

SMS Pharma revenue down 9%

Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market

Biocon Q2FY23 net profit slips 10% to Rs 168 Cr; Revenue up 26%

Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%

Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers

Ayu Health receives US $27 million additional funding

The company is making its entry into the Hyderabad market through its unique asset-light business model

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.

Dr. Mansukh Mandaviya and Bhagwanth Khuba to grace Silver Jubilee function of NPPA

To mark the occasion, Integrated Pharmaceutical Database Management System 2.0 (IPDMS 2.0), an integrated responsive cloud-based application developed by NPPA with technical support from C-DAC will be launched

Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets

Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA

ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.